|
|
| Product Name: | AD80 | | Synonyms: | AD80;1-(4-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)-3-(2-methyl-5-(trifluoromethyl)phenyl)urea;Reaxys ID: 27131146;Urea, N-[4-[4-amino-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]phenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-;1-(4-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenyl)-3-(2-fluoro-5-(trifluoromethyl)phenyl)urea;Inhibitor,Raf,AD 80,inhibit,Raf kinases,AD-80,Ribosomal S6 Kinase (RSK),S6K,RET,AD80,Src;AD80, 10 mM in DMSO;AD80 ，S8518 | | CAS: | 1384071-99-1 | | MF: | C22H19F4N7O | | MW: | 473.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1384071-99-1.mol |  |
| Boiling point | 530.9±50.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO:122.0(Max Conc. mg/mL);257.69(Max Conc. mM)
Ethanol:94.0(Max Conc. mg/mL);198.55(Max Conc. mM) | | pka | 12.47±0.70(Predicted) | | form | Solid | | color | White to off-white |
| Uses | AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity. | | Biological Activity | AD80, a multi-kinase inhibitor, is more active against human RET (c-RET), BRAF, S6K, and SRC, but less active against mTOR than AD57 or AD58. Its IC50 value for RET (c-RET) is 4 nM. | | in vivo | AD80 is a potent RET inhibitor with favorable pharmacokinetic profile in clinically relevant RET fusion-driven tumor models. In patient-derived xenograft species, AD80 effectively reduced RET-rearranged tumor size. | | target | | Target | Value | Raf
(Cell-free) | | | Src < br/> (Cell-free) | | S6 Kinase
(Cell-free) | | RET V804M
(Cell-free assay) | 0.4 nM | RET V804L
(Cell-free assay) | 0.6 nM |
| | IC 50 | p70S6K; RAF; RET; SRC | | References | [1] Dar AC, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.Nature. 2012 Jun 6;486(7401):80-4. DOI:10.1038/nature11127
[2] Liu H, et al. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia.Cell Rep. 2017 Feb 28;18(9):2088-2095. DOI:10.1016/j.celrep.2017.02.022 |
| | AD80 Preparation Products And Raw materials |
|